News

StageBio is honored to introduce Dr. Juliana Lee, BVSc, MS, DACVP as Interim Director, Medical Device Pathology.

It is with great honor that we announce the promotion of Dr. Stephanie Shrader as Director of General Toxicologic Pathology at StageBio.

It is with great honor that we introduce Dr. Tracey Papenfuss as a Senior Pathologist at StageBio. We are happy to have her on the team and look forward to all she will accomplish!

StageBio StageBio is honored to introduce Ellen Humphrey as Chief People and Business Integration Officer to our team. We are happy to have her on board and look forward to all she will accomplish!

StageBio is honored to introduce Dr. Lauren Peiffer as a Pathologist to our team. We are happy to have her on board and look forward to all she will accomplish!

It is with great honor that we introduce Dr. Suresh Muthupalani as a Senior Pathologist at StageBio. We are happy to have him on the team and look forward to all he will accomplish!

StageBio Announces Lori Ball has been appointed as new CEO for StageBio, who brings a history of global leadership in the life sciences industry. Ms Ball will succeed Tom Galati, former CEO and Founder of StageBio, who will remain an integral part of the board of directors. Ms Ball will begin her role January 18, 2022.

In a recent ACT 2021 Talking Tox webinar titled “Safety of E-Cigarette Products – A Toxicological Challenge,” I provided scientific guidance on pathology endpoints for inhalation studies. During my segment, I discussed the special planning necessary to optimize histopathology results when studying test articles dosed via the inhalation route (nose-only, head, or whole-body exposure).

It is with great honor that we introduce Dr. Eric Lee as a Senior Pathologist at StageBio. We are happy to have him on the team and look forward to all he will accomplish!

StageBio’s very own Dr. Thomas Lemarchand will join his colleagues at the 63rd annual American Society of Hematology (ASH) meeting to present their findings on the newly designated Lambda Myeloma Antigen (LMA). During the presentation, which is titled, “A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias,” Dr. Lemarchand and his team will detail the methods they used to detect the LMA, including flow cytometry on key cell lines and immunohisto-chemistry on normal and pathologic human frozen tissues and results, with what this could mean for myeloma treatment and understanding the pathogenesis.